FDA Determines Regulatory Review Period for BONIVA Patent Extension

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for BONIVA, a human drug product, in response to a patent extension application submitted to the Director of Patents and Trademarks at the US Department of Commerce.